What the Rosa Medical Robot Actually Is
Rosa is Zimmer Biomet's ROSA Knee System for robot-assisted total knee arthroplasty, and ROSA Brain and ROSA ONE Spine for cranial and spinal navigation. The platform originated with French company Medtech SA, which Zimmer Biomet acquired in 2016 before rebranding and expanding it.
The FDA cleared Rosa Knee under 510(k) K183020 in 2019 as a stereotactic surgical instrument that assists the surgeon in bone resection during TKA. Rosa Brain has a longer regulatory history, with the earlier Medtech ROSA cleared under 510(k) K093644.
The buyer-first framing: Rosa is not one robot. A hospital evaluating Rosa Knee is running an orthopedic capital purchase against Mako and Cori. A hospital evaluating Rosa Brain is running a neurosurgery purchase against Medtronic Stealth-guided systems and Brainlab. The vendor is the same. The clinical workflow, disposables, and comparison set are not.
| System | Vendor | Primary use | FDA pathway | Key input |
|---|---|---|---|---|
| ROSA Knee | Zimmer Biomet | Total knee arthroplasty | 510(k) K183020 | Imageless or CT-based planning |
| ROSA Brain | Zimmer Biomet | Stereotactic cranial procedures | 510(k) K093644 (Medtech ROSA) | Preoperative MRI/CT |
| ROSA ONE Spine | Zimmer Biomet | Pedicle screw placement, spinal navigation | 510(k) cleared | Intraoperative imaging + planning |
| Mako | Stryker | Knee, hip, and partial knee arthroplasty | 510(k) cleared | Mandatory preoperative CT |
| CORI | Smith+Nephew | Knee arthroplasty (handheld) | 510(k) cleared | Imageless intraoperative mapping |
Rosa Knee vs Mako vs Cori: The Orthopedic Comparison That Matters
Rosa Knee is imageless-capable, meaning it can plan a knee using intraoperative bone landmarks rather than requiring a preoperative CT — a workflow difference that Zimmer Biomet emphasizes against Stryker's Mako, which uses a mandatory preoperative CT protocol. Smith+Nephew's CORI is also imageless and handheld rather than a fixed arm.
Peer-reviewed comparisons remain early. A 2023 systematic review in The Journal of Arthroplasty and multiple Rosa-specific series such as Parratte et al. report improved alignment accuracy versus manual TKA, but do not yet show a decisive long-term functional advantage of one robotic platform over another.
The honest buyer read: the choice between Rosa, Mako, and CORI is more often driven by the surgeon's existing implant preference — Zimmer Biomet Persona knees with Rosa, Stryker Triathlon with Mako, Smith+Nephew Journey II or Legion with CORI — than by robot capability alone. Hospitals that pick a robot without confirming implant lock-in end up buying the ecosystem twice.
- Rosa Knee is imageless-capable; Mako requires preoperative CT; CORI is imageless and handheld.
- Each platform is tightly coupled to its parent company's implant line.
- Reported alignment accuracy improvements are real but similar across the three systems.
- Long-term revision and patient-reported outcome data comparing platforms head-to-head is still limited.
- Total cost of ownership includes disposables and implants, not just the capital price of the arm.
Rosa Brain and Rosa ONE Spine: The Neurosurgery Case
Rosa Brain is used for stereotactic biopsy, deep brain stimulation (DBS) electrode placement, and stereo-electroencephalography (SEEG) depth-electrode implantation for epilepsy mapping. Published series such as González-Martínez et al. on robotic SEEG and Vakharia et al. report accuracy and workflow-time improvements versus frame-based stereotaxy.
Rosa ONE Spine competes primarily with Medtronic Mazor X and Globus ExcelsiusGPS for pedicle screw placement. All three add planning software and rigid guidance to intraoperative imaging, and the differentiation is largely integration with each vendor's own imaging and implant line.
The clinical case for a neurosurgery robot is strongest at centers with high SEEG or complex-spine volume, where the reduction in per-electrode or per-screw time compounds meaningfully. At low volume, the robot is a large capital outlay against a small number of cases per year.
Ottava, Auris Ion, and the Adjacent Platforms Buyers Confuse With Rosa
Johnson & Johnson's Ottava is a soft-tissue general-surgery robot that J&J MedTech has publicly described as in development, with first clinical cases initiated in 2024. Ottava is not a Rosa competitor — it is aimed at the laparoscopic space currently dominated by Intuitive Surgical's da Vinci. Buyers who ask about "the Ottava medical robot" alongside Rosa are usually comparing two different categories.
J&J MedTech's Monarch and Intuitive's Ion endoluminal system — the successor concept to the Auris platform Intuitive acquired in its 2019 Auris Health deal — are robotic bronchoscopy platforms for peripheral lung nodule biopsy. Again, not a Rosa comparison, but frequently cross-shopped by hospitals building out a robotics program across multiple service lines.
The older Zeus robotic surgical system from Computer Motion was merged into Intuitive Surgical in 2003 and is no longer sold. Any 'Zeus medical robot' listing in the market today is either legacy equipment or a naming coincidence with an unrelated device.
| Platform | Vendor | Category | Status |
|---|---|---|---|
| Ottava | Johnson & Johnson MedTech | Soft-tissue general surgery | First clinical cases 2024, not yet commercially cleared |
| da Vinci 5 | Intuitive Surgical | Soft-tissue multi-specialty | FDA cleared, in commercial rollout |
| Ion | Intuitive Surgical | Robotic bronchoscopy | FDA cleared, in commercial use |
| Monarch | J&J MedTech (Auris) | Robotic bronchoscopy | FDA cleared, in commercial use |
| Zeus | Computer Motion (defunct) | Soft-tissue surgery | Discontinued after 2003 Intuitive merger |
What Rosa Actually Costs and How Hospitals Deploy It
Zimmer Biomet does not publish list prices. Industry reporting and hospital financial disclosures place a Rosa Knee system in the roughly $750,000 to $1.2 million range for the capital equipment, with additional per-case disposables, service contracts, and training. Comparable estimates for Mako are in the $1 million to $1.25 million range per AAOS Now coverage of orthopedic robotics economics. Treat any single number here as a quote-only estimate, not a confirmed list price.
Hospitals typically deploy Rosa Knee through a shared-service model — one robot, multiple surgeons, dedicated OR block time — and Zimmer Biomet offers financing and utilization-based programs that shift some of the capital outlay into per-procedure fees. AHRQ and CMS reimbursement do not currently pay a premium for robotic-assisted TKA versus manual TKA, so the ROI case rests on volume growth, length-of-stay reduction, and surgeon recruitment rather than direct reimbursement.
The line item most CFO reviews miss is the second-year cost: annual service contracts commonly run 8-12% of capital price at high-end medical robotics, plus retraining as surgeons and OR staff turn over. A five-year total cost of ownership is closer to the honest number than the sticker.
Bottom Line
Rosa is a credible platform in both orthopedics and neurosurgery, but the buying decision is really three decisions: which service line, which implant ecosystem, and what per-year case volume justifies the capital. Compare Rosa Knee against Mako and CORI on implant lock-in as much as on the robot itself, evaluate Rosa Brain and Rosa ONE Spine against Mazor X and ExcelsiusGPS on imaging integration, and do not cross-shop it against Ottava, Ion, or Monarch, which sit in different categories entirely.
Before any Rosa quote, confirm the surgeon's implant preference, five-year service costs, and expected annual case volume — the robot economics live in those three numbers.
FAQs
Is Rosa Knee better than Mako?
Neither is decisively better in published outcomes. Rosa Knee is imageless-capable while Mako requires a preoperative CT, and each is coupled to its parent company's implant line — Zimmer Biomet Persona for Rosa and Stryker Triathlon for Mako.
How much does a Rosa medical robot cost?
Zimmer Biomet does not publish list prices. Industry estimates place Rosa Knee capital cost at roughly $750,000 to $1.2 million, plus per-case disposables and a service contract. Treat any figure as quote-only until confirmed with the vendor.
What is Ottava and is it a Rosa competitor?
Ottava is Johnson & Johnson MedTech's soft-tissue surgical robot, in early clinical cases as of 2024. It competes with Intuitive's da Vinci in general surgery, not with Rosa, which is an orthopedic and neurosurgery platform.
Is the Zeus medical robot still available?
No. The original Zeus robotic surgical system from Computer Motion was discontinued after Computer Motion merged with Intuitive Surgical in 2003. Any current 'Zeus' branding in medical robotics refers to unrelated devices.
Which hospitals should buy a Rosa Brain rather than a Rosa Knee?
Rosa Brain fits centers with high SEEG, DBS, or stereotactic biopsy volume where per-case time savings compound. Rosa Knee fits high-volume total-knee-arthroplasty programs already committed to Zimmer Biomet implants.